Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trialsEric L. Simpson, Kristian Reich, Jacob P. Thyssen et al.|British Journal of Dermatology|2020Cited by 377
Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placeboThomas Dirschka, Peter Radny, R. Dominicus et al.|British Journal of Dermatology|2011Cited by 181
Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (<scp>UNCOVER</scp>‐1, <scp>UNCOVER</scp>‐2 and <scp>UNCOVER</scp>‐3)Alan Menter, Kristian Reich, Richard B. Warren et al.|Journal of the European Academy of Dermatology and Venereology|2017Cited by 74
Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)Kristian Reich, Howard Sofen, Craig L. Leonardi et al.|Journal of Dermatological Treatment|2016Cited by 56